Singapore at a glance
- Population
- 6.1 million 2025
- Life expectancy at birth
- 83.3 years, 2024
- People aged 65 and over
- 14.2 % of people, 2025
- Health spending per person
- 3,922 US$ per person, 2023
- Doctors
- 2.83 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
Singapore Polygenic Risk Scores Market Industry Trends and Forecast to 2034: Segmented by (Condition, User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $0.2 Mn | — | — |
| 2025 (base) | $0.3 Mn | +$0.0 Mn | — |
| 2026 (forecast) | $0.3 Mn | +$0.1 Mn | +18.5% |
| 2027 (forecast) | $0.4 Mn | +$0.1 Mn | +40.4% |
| 2028 (forecast) | $0.5 Mn | +$0.1 Mn | +66.4% |
| 2029 (forecast) | $0.6 Mn | +$0.1 Mn | +97.2% |
| 2030 (forecast) | $0.7 Mn | +$0.1 Mn | +133.7% |
| 2031 (forecast) | $0.8 Mn | +$0.1 Mn | +176.9% |
| 2032 (forecast) | $0.9 Mn | +$0.1 Mn | +228.1% |
| 2033 (forecast) | $1.1 Mn | +$0.2 Mn | +288.8% |
| 2034 (forecast) | $1.3 Mn | +$0.2 Mn | +360.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $0.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 18.5% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Condition and user (see all) |
| Key players | Genomics plc, Allelica, Myriad Genetics, Inc., 23andMe, Color Health (see all) |
| Regulator in Singapore | HSASource: Health Sciences Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Polygenic risk scores combine many small genetic effects to estimate a person's risk of common diseases such as heart disease and diabetes.
Key segments of the polygenic Risk Scores market include condition (Cardiovascular Disease, Cancer and Diabetes) and user (Clinicians, Consumers and Researchers).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the polygenic Risk Scores market.
Routine use of genomics in screening, pharmacy and primary care gives the polygenic Risk Scores market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the polygenic Risk Scores market.
The polygenic Risk Scores market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices must be registered with the Health Sciences Authority (HSA), except low-risk Class A devices.[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.[2]
[1] Health Sciences Authority. Checked 14 Nov 2026.
[2] CPF Board, MediShield Life. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how polygenic Risk Scores products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Singapore.
What doctors and scientists are doing in Polygenic Risk Scores right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
From our blog
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Singapore
Singapore
Singapore
Pharmaceuticals · Singapore
Digital Health · Singapore
Healthcare Services · Singapore
Healthcare Services · Singapore
Digital Health · Singapore
Healthcare Services · Singapore